WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days

WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden